The Latest

This Week in HIV Research: Additional Nuance on Pregnancy and Antiretrovirals

Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: A Long-Acting Popularity Contest

The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.

By Barbara Jungwirth and Myles Helfand

Dolutegravir: Need to Consider All Pros and Cons Before Switching in Pregnancy

A recent case study illustrates the complexity of managing women in early stages of pregnancy presenting on a dolutegravir-based regimen, and the need for careful consideration when responding to new data.

By Polly Clayden for HIV i-Base

Switching From Atripla to Complera

Now that the best-selling Atripla has a real competitor, an important question becomes, can people switch from Atripla to the new Complera?

While switching to a new and improved drug or regimen is common, there was a concern about switching here bec...

By Jeff Berry and Enid Vazquez for Positively Aware